FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899244918> ?p ?o ?g. }

• W2899244918 endingPage "490" @default.
• W2899244918 startingPage "479" @default.
• W2899244918 abstract "Two elvitegravir/cobicistat-based therapies combined with emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) or emtricitabine/tenofovir alafenamide fumarate (EVG/c/FTC/TAF) are currently available for HIV patients. This study evaluated the modifications in the lipid profile of patients who received these treatments in the last three years at our institution. A retrospective observational study in HIV-infected patients who received EVG/c/FTC/TDF or EVG/c/FTC/TAF from January 2015 to January 2018 at a reference hospital in northwestern Spain was carried out. Epidemiological, clinical and immunovirological data were recorded. A statistical analysis was performed using SPSS software. A total of 384 EVG/c-based therapies were initiated during the study period, 151 EVG/c/FTC/TDF and 233 EVG/c/FTC/TAF. A significantly negative influence in all the lipid profile parameters in experienced patients and total cholesterol (TC), and LDL-C in naïve patients were observed after 48 weeks of treatment with EVG/c/FTC/TAF, while these parameters remained stable in the EVG/c/FTC/TDF group. During follow-up, a greater proportion of patients had lipid levels above the normal range (63.1% TC, 56.2% LDL-C) and new lipid-modifying drugs were prescribed (11.9%) in the EVG/c/FTC/TAF group. The number of cardiovascular risk factors (OR 1.66 [95% CI 1.01-2.72]; P = 0.043) was recognised as an independent predictor of lipid-lowering prescription for patients treated with both EVG/c/FTC/TDF and EVG/c/FTC/TAF. For patients treated with EVG/c/FTC/TAF, the mean total cholesterol to HDL ratio in the first 48 weeks of the study treatment was associated with a higher likelihood of lipid-lowering prescription in multivariate analysis (OR 1.6 [95% CI 1.12-2.52]; P = 0.011). Significant changes in lipid profile have been observed in patients who have received EVG/c/FTC/TAF. It was necessary to prescribe almost twice the number of lipid-lowering drugs to patients who received EVG/c/FTC/TAF (11.9%) vs EVG/c/FTC/TDF (4.7%)." @default.
• W2899244918 created "2018-11-09" @default.
• W2899244918 creator A5001289474 @default.
• W2899244918 creator A5001444684 @default.
• W2899244918 creator A5006274830 @default.
• W2899244918 creator A5014503266 @default.
• W2899244918 creator A5018111427 @default.
• W2899244918 creator A5027990204 @default.
• W2899244918 creator A5040657204 @default.
• W2899244918 creator A5042759105 @default.
• W2899244918 creator A5057854777 @default.
• W2899244918 creator A5058402271 @default.
• W2899244918 creator A5062284049 @default.
• W2899244918 date "2018-12-07" @default.
• W2899244918 modified "2023-10-18" @default.
• W2899244918 title "Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine" @default.
• W2899244918 cites W1964217313 @default.
• W2899244918 cites W1965312995 @default.
• W2899244918 cites W2019724200 @default.
• W2899244918 cites W2041929630 @default.
• W2899244918 cites W2055922999 @default.
• W2899244918 cites W2056779298 @default.
• W2899244918 cites W2113255660 @default.
• W2899244918 cites W2125377515 @default.
• W2899244918 cites W2138694347 @default.
• W2899244918 cites W2149185709 @default.
• W2899244918 cites W2161193921 @default.
• W2899244918 cites W2196190612 @default.
• W2899244918 cites W2301510887 @default.
• W2899244918 cites W2322502550 @default.
• W2899244918 cites W2530415252 @default.
• W2899244918 cites W2591843569 @default.
• W2899244918 cites W2609028956 @default.
• W2899244918 cites W2744439415 @default.
• W2899244918 cites W2752494178 @default.
• W2899244918 cites W2785447450 @default.
• W2899244918 cites W2790864025 @default.
• W2899244918 cites W2791939743 @default.
• W2899244918 cites W2800075375 @default.
• W2899244918 cites W2809064859 @default.
• W2899244918 cites W4238444439 @default.
• W2899244918 doi "https://doi.org/10.1111/bcpt.13161" @default.
• W2899244918 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30388308" @default.
• W2899244918 hasPublicationYear "2018" @default.
• W2899244918 type Work @default.
• W2899244918 sameAs 2899244918 @default.
• W2899244918 citedByCount "35" @default.
• W2899244918 countsByYear W28992449182019 @default.
• W2899244918 countsByYear W28992449182020 @default.
• W2899244918 countsByYear W28992449182021 @default.
• W2899244918 countsByYear W28992449182022 @default.
• W2899244918 countsByYear W28992449182023 @default.
• W2899244918 crossrefType "journal-article" @default.
• W2899244918 hasAuthorship W2899244918A5001289474 @default.
• W2899244918 hasAuthorship W2899244918A5001444684 @default.
• W2899244918 hasAuthorship W2899244918A5006274830 @default.
• W2899244918 hasAuthorship W2899244918A5014503266 @default.
• W2899244918 hasAuthorship W2899244918A5018111427 @default.
• W2899244918 hasAuthorship W2899244918A5027990204 @default.
• W2899244918 hasAuthorship W2899244918A5040657204 @default.
• W2899244918 hasAuthorship W2899244918A5042759105 @default.
• W2899244918 hasAuthorship W2899244918A5057854777 @default.
• W2899244918 hasAuthorship W2899244918A5058402271 @default.
• W2899244918 hasAuthorship W2899244918A5062284049 @default.
• W2899244918 hasBestOaLocation W28992449182 @default.
• W2899244918 hasConcept C126322002 @default.
• W2899244918 hasConcept C142462285 @default.
• W2899244918 hasConcept C159047783 @default.
• W2899244918 hasConcept C2777068322 @default.
• W2899244918 hasConcept C2779778239 @default.
• W2899244918 hasConcept C2780524789 @default.
• W2899244918 hasConcept C2911190787 @default.
• W2899244918 hasConcept C2993143319 @default.
• W2899244918 hasConcept C3013748606 @default.
• W2899244918 hasConcept C71924100 @default.
• W2899244918 hasConcept C90924648 @default.
• W2899244918 hasConcept C98274493 @default.
• W2899244918 hasConceptScore W2899244918C126322002 @default.
• W2899244918 hasConceptScore W2899244918C142462285 @default.
• W2899244918 hasConceptScore W2899244918C159047783 @default.
• W2899244918 hasConceptScore W2899244918C2777068322 @default.
• W2899244918 hasConceptScore W2899244918C2779778239 @default.
• W2899244918 hasConceptScore W2899244918C2780524789 @default.
• W2899244918 hasConceptScore W2899244918C2911190787 @default.
• W2899244918 hasConceptScore W2899244918C2993143319 @default.
• W2899244918 hasConceptScore W2899244918C3013748606 @default.
• W2899244918 hasConceptScore W2899244918C71924100 @default.
• W2899244918 hasConceptScore W2899244918C90924648 @default.
• W2899244918 hasConceptScore W2899244918C98274493 @default.
• W2899244918 hasIssue "4" @default.
• W2899244918 hasLocation W28992449181 @default.
• W2899244918 hasLocation W28992449182 @default.
• W2899244918 hasOpenAccess W2899244918 @default.
• W2899244918 hasPrimaryLocation W28992449181 @default.
• W2899244918 hasRelatedWork W2264012645 @default.
• W2899244918 hasRelatedWork W2320601665 @default.
• W2899244918 hasRelatedWork W2577777925 @default.
• W2899244918 hasRelatedWork W2730313341 @default.

• next